- Home
- ECVT vs VIR Comparison
ECVT vs VIR Comparison
Compare ECVT & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ECVT | VIR |
|---|---|---|
| Founded | 1935 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ECVT | VIR |
|---|---|---|
| Price | $12.20 | $8.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $13.60 | ★ $19.63 |
| AVG Volume (30 Days) | 2.2M | ★ 4.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $723,515,000.00 | $68,556,000.00 |
| Revenue This Year | $27.44 | N/A |
| Revenue Next Year | $5.65 | $1,049.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.70 | N/A |
| 52 Week Low | $5.24 | $4.16 |
| 52 Week High | $12.38 | $10.91 |
Technical Indicators
Market Signals| Indicator | ECVT | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 63.47 | 47.29 |
| Support Level | $7.77 | $8.67 |
| Resistance Level | $12.36 | $10.29 |
| Average True Range (ATR) | 0.40 | 0.48 |
| MACD | 0.05 | -0.17 |
| Stochastic Oscillator | 90.00 | 5.74 |
Price Performance
Historical ComparisonAbout ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.